Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
Details : Norursodeoxycholic acid is a synthetic derivative of UDCA, shows promise for Non-Alcoholic Fatty Liver Disease by activating the AMPK pathway to reduce liver fat, inflammation, and apoptosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2025
Lead Product(s) : Ursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Alveolus Bio
Deal Size : Undisclosed
Deal Type : Financing
Alveolus Bio Secures Investment from Shilpa Medicare to Advance Pulmonary Therapeutics
Details : The funding will be used accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform in diseases such as COPD, BPD and Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
August 04, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Alveolus Bio
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Recombinant Human Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Orion and Shilpa Medicare Partner on Recombinant Human Albumin In Europe
Details : Orion will gain exclusive right to distribute, market and sell Shilpa’s sRbumin, a recombinant human albumin in Europe.
Product Name : sRbumin
Product Type : Protein
Upfront Cash : Undisclosed
May 23, 2025
Lead Product(s) : Recombinant Human Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Norursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare receives CDSCO SEC Nod for IND Nor UDCA tablets for NAFLD treatment
Details : SMLNUD07 (norursodeoxycholic acid) tablets 500 mg is recommended marketing authorization for treating non-alcoholic fatty liver disease (nafld) by CDSCO.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Norursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Receives US Approval for Varenicline Tablets, 0.5 mg and 1 mg
Details : Varenicline Tartrate is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment.
Product Name : Chantix-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Wins SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid in NASH Market
Details : SMLNUD07 (nor ursodeoxycholic acid) tablets 500 mg is recommended marketing authorization for treating non-alcoholic fatty liver disease (nafld) by CDSCO.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : Norursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal and Shilpa Gain FDA Approval for BORUZU™, Ready-to-Use Bortezomib
Details : Bortezomib injection is a proteasome inhibitor approved for treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.
Product Name : Boruzu
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Albumin,Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Completes Phase 1 Trial of Human Albumin as First in India
Details : sRbumin (recombinant human albumin) is a synthetic form of human serum albumin protein, which is currently being evaluated for the treatment of accidents, burns, and surgeries.
Product Name : sRbumin
Product Type : Protein
Upfront Cash : Inapplicable
August 28, 2024
Lead Product(s) : Recombinant Human Albumin,Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Launches Pemetrexed Injection
Details : Pemrydi (pemetrexed) is the first ready-to-use formulation approved for commercialization in the US market. It is indicated for patients suffering from non-small cell lung cancer.
Product Name : Pemrydi RTU
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Shilpa Medicare Gets Europe Approval for Varenicline Tablets, 0.5mg and 1mg
Details : Varenicline is a nAChRα4&β2 (Neuronal acetylcholine receptor; alpha4/beta2) agonist, small molecule drug. It is approved for the treatment of smoking cessation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable